Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
🌍 Cross-language spread
PULSE detected this story across 3 language editions of the world's news.
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength" is generating significant coverage in the Business category, with 9 articles from 9 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, Investor's Business Daily, Seeking Alpha and 10TV. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 18d ago.
Quick answers
Why is "Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda sho" trending?
Because 9 independent news sources published 9 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (9)
- Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates Yahoo Finance · 20d ago
- Merck Beats, But Can Shares Outplay The Cancer Vaccine News? Investor's Business Daily · 20d ago
- Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) Seeking Alpha · 20d ago
- Merck: Q3 Earnings Snapshot 10TV · 20d ago
- Merck Earnings Blow Past Estimates. Why Wall Street Has Its Eyes on the Coming Year. Barron's · 20d ago
- Merck Revenue Up on Keytruda, Winrevair Growth WSJ · 20d ago
- Dear Merck Stock Fans, Mark Your Calendars for October 29 Barchart.com · 20d ago
- Merck Boosts Profit Forecast as Key Medicines Top Estimates Bloomberg · 20d ago
- Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength CNBC · 20d ago
Topics
Related trends
‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the promising news on cancer vaccines.
Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence by 42% according to recent coverage.
First personalised cancer vaccine cuts risk of disease returning in major trial
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts melanoma recurrence or death risk by 42%.
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
Exclusive | She was ready to die. Now she’s in remission
New developments in personalized mRNA cancer vaccines show promise for melanoma and breast cancer, though hurdles in public perception remain.
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.